Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P10721 (
c-kit
)
6,575
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Activating mutations of
c-Kit
are frequently found in acute myeloid leukemia (AML) patients harboring t(8;21) chromosomal translocation generating a fusion protein AML1-ETO. Here we show that an active mutant of
c-Kit
cooperates with AML1-ETO to induce AML in mouse bone marrow transplantation models. Leukemic cells expressing AML1-ETO with
c-Kit
(D814V) were serially transplantable. Transplantation experiments indicated that lineage(-)
c-Kit
(+)Sca-1(+) (KSL) leukemic cells, but not lineage(+) leukemic cells, were enriched for leukemia stem cells (LSCs). Comparison of gene expression profiles between KSL leukemic and normal cells delineated that
CD200R1
was highly expressed in KSL leukemic cells as compared with KSL normal cells. Upregulation of
CD200R1
was verified in lineage(-) leukemic cells, but not in lineage(+) leukemic cells.
CD200R1
expression in the lineage(-) leukemic cells was not correlated with the frequency of LSCs, indicating that
CD200R1
is not a useful marker for LSCs in these models. Interestingly,
CD200R1
was upregulated in KSL cells transduced with AML1-ETO, but not with other leukemogenic mutants, including
c-Kit
(D814V), AML1(D171N), and AML1(S291fsX300). Consistently, upregulation of
CD200R1
in lineage(-) leukemic cells was observed only in the BM of mice suffering from AML1-ETO-positive leukemia. In conclusion, AML1-ETO upregulated
CD200R1
in lineage(-) cells, which was characteristic of AML1-ETO-positive leukemia in mice.
...
PMID:Upregulation of CD200R1 in lineage-negative leukemic cells is characteristic of AML1-ETO-positive leukemia in mice. 2309 87